Your browser doesn't support javascript.
loading
Progress of drugs targeting E3 ubiquitin ligase / 中国药理学通报
Chinese Pharmacological Bulletin ; (12): 749-755, 2021.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-1014430
Responsible library: WPRO
ABSTRACT
The ubiquitin-proteasome pathway is one of the most important pathways of cell protein degradation in eukaryotes, and plays an important role in the regulation of cell proliferation, differentiation, apoptosis, DNA repair and other physiological activities. E3 ubiquitin ligase is the major component of ubiquitinproteasome system, which is responsible for substrate recognition. The abnormal regulation of E3 ubiquitin ligase may cause many diseases such as cancer, Alzheimer's disease and Parkinson's disease. Here, we summarizes the progress of drugs targeting E3 ubiquitin ligase in cancer, Alzheimer's disease, Parkinson's disease, diabetic complications, atherosclerosis, and inflammatory bowel diseases. At present, only a few of small molecule antagonists or agonists targeting E3 ubiquitin ligase are under development. The study of natural products in China is leading the way in the world, and numerous natural products have been identified for pharmacological effects on E3 ubiquitin ligase, which may open up a new avenue for multiple complex diseases.

Full text: Available Database: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Pharmacological Bulletin Year: 2021 Document type: Article
Full text: Available Database: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Pharmacological Bulletin Year: 2021 Document type: Article
...